Survivorship Issues in Testicular Cancer

Authors

  • Marco Pisino, MD Division of Medical Oncology, Vito Fazzi Hospital, Lecce, Italy
  • Lucia Nappi, MD Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada British Columbia Cancer – Vancouver Centre, Department of Medicine – Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada

DOI:

https://doi.org/10.58931/cot.2024.1223

Abstract

Testicular cancer (TC) is the most prevalent tumor in young men aged 15–40 years, with an annual incidence of 3–11 new cases per 100,000 males in Western countries. In 2020, the International Agency for Research on Cancer reported 74,458 newly diagnosed cases of TC globally. The etiology of TC is complex and includes both genetic and environmental factors. The prognosis of TC is excellent with a >90% cure rate and a >95% 5-year survival rate with appropriate treatment. Treatments for TC include active surveillance, chemotherapy, radiotherapy, and retroperitoneal lymph node dissection, depending on the clinical stage and tumor subtype. It is crucial that patients receive information on the diagnosis, therapeutic management options, consequences of treatments, and surveillance protocols, which allows the patient to play an active role in the decision-making process. Fear of recurrence often affects TC survivors. Therefore, it is essential to fully involve the patient in the choice of the treatment to ensure an optimal compliance, especially when selecting the active surveillance strategy. In the modern era, in light of the excellent outcomes achieved in TC management, one of the high priorities is to deliver curative treatments while minimizing long-term toxicity. This focus can have a positive impact on quality of life and life expectancy of TC survivors. 

Author Biographies

Marco Pisino, MD, Division of Medical Oncology, Vito Fazzi Hospital, Lecce, Italy

Dr. Pisino is a medical oncologist at the “Vito Fazzi” Hospital in Lecce, Italy, with a clinical practice specializing in genitourinary malignancies. He completed his medical degree and training at the University of Parma, followed by an oncology residency at the University of Bari. Most recently, he pursued a fellowship in Genitourinary Oncology through the Italian Foundation “La Clessidra” at the University of British Columbia under Dr. Lucia Nappi’s supervision, with a research focus on testicular cancer. 

Lucia Nappi, MD, Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada British Columbia Cancer – Vancouver Centre, Department of Medicine – Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada

Dr. Lucia Nappi is a medical oncologist - clinician scientist, MD and PhD. She is an assistant professor in the department of Urologic Sciences at the University of British Columbia and a senior research scientist at the Vancouver Prostate and works as medical oncologist in the GU group at the BC Cancer in Vancouver. Her main research focus involves the discovery and validation of biomarkers in GU cancers, mainly in prostate and testis cancer patients. She has got several grants and awards including the Prostate Cancer Foundation Young Investigator award and the Michael Smith Foundation Health Professional Investigator award (2020), the operational CIHR grant in 2021, the R37 NIH grant and the career development award from the US department of defense (2022). She is the vice-chair of the SWOG Adolescent and Young Adults (AYA) committee and the chair of the international SWOG-S1823/CCTG GCC.1 clinical trial. 

References

Cook MB, McGlynn KA. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev. 2010;19(5):1151-1159. doi:10.1158/1055-9965.Epi-10-0031

Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore). 2018;97(37):e12390. doi:10.1097/md.0000000000012390

Giona S. The Epidemiology of Testicular Cancer. In: Barber N, Ali A, editors. Urologic Cancers Brisbane (AU): Exon Publications; 2022.

Smith ZL, Werntz RP, Eggener SE. Testicular cancer: epidemiology, diagnosis, and management. Med Clin North Am. 2018;102(2):251-264. doi:10.1016/j.mcna.2017.10.003

Condello C, Rescigno P, Ottaviano M, Nappi L, Tortora M, de Placido S, et al. Clinical features and psychological aspects of the decision-making process in stage I testicular germ cell tumors. Future Oncol. 2018;14(16):1591-1599. doi:10.2217/fon-2017-0670

Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T, et al. Testicular cancer. Nat Rev Dis Primers. 2018;4(1):29. doi:10.1038/s41572-018-0029-0

Della Latta V, Cecchettini A, Del Ry S, Morales MA. Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions. Pharmacol Res. 2015;97:122-130. doi:10.1016/j.phrs.2015.04.012

Moeller A, Rodriguez-Lecompte JC, Wang L, Gauldie J, Kolb M. Models of pulmonary fibrosis. Drug Discovery Today: Disease Models. 2006;3(3):243-249. doi:https://doi.org/10.1016/j.ddmod.2006.09.006

Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(5):543-548. doi:10.1164/rccm.200209-1112OC

Fosså SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst. 2007;99(7):533-544. doi:10.1093/jnci/djk111

O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14(1):91-96. doi:10.1093/annonc/mdg020

Higuchi K, Yanagawa T. Evaluating dose of cisplatin responsible for causing nephrotoxicity. PLoS One. 2019;14(4):e0215757. doi:10.1371/journal.pone.0215757

Hansen SW, Groth S, Daugaard G, Rossing N, Rørth M. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol. 1988;6(11):1728-1731. doi:10.1200/jco.1988.6.11.1728

Fosså SD, Aass N, Winderen M, Börmer OP, Olsen DR. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol. 2002;13(2):222-228. doi:10.1093/annonc/mdf048

Meijer C, de Vries EG, Marmiroli P, Tredici G, Frattola L, Cavaletti G. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology. 1999;20(6):883-887.

McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005;18(2):305-313. doi:10.1016/j.nbd.2004.09.013

Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol. 2012;30(3):300-307. doi:10.1200/jco.2011.37.4025

von Schlippe M, Fowler CJ, Harland SJ. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer. 2001;85(6):823-826. doi:10.1054/bjoc.2001.2006

Bauer CA, Brozoski TJ. Cochlear structure and function after round window application of ototoxins. Hear Res. 2005;201(1-2):121-131. doi:10.1016/j.heares.2004.09.008

Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013;34(8):458-469. doi:10.1016/j.tips.2013.05.006

Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol. 2016;34(23):2712-2720. doi:10.1200/jco.2016.66.8822

Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydøy M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol. 2012;30(30):3752-3763. doi:10.1200/jco.2012.43.4431

Becher R, Schütt P, Osieka R, Schmidt CG. Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiaminoplatinum II. J Cancer Res Clin Oncol. 1980;96(2):219-222. doi:10.1007/bf00405506

Berman IJ, Mann MP. Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer. 1980;45(4):764-766. doi:10.1002/1097-0142(19800215)45:4<764::aid-cncr2820450425>3.0.co;2-g

Dulz S, Asselborn NH, Dieckmann KP, Matthies C, Wagner W, Weidmann J, et al. Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. J Cancer Res Clin Oncol. 2017;143(7):1319-1325. doi:10.1007/s00432-017-2384-8

Teutsch C, Lipton A, Harvey HA. Raynaud’s phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep. 1977;61(5):925-926.

Brydøy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009;101(24):1682-1695. doi:10.1093/jnci/djp413

Orre IJ, Fosså SD, Murison R, Bremnes R, Dahl O, Klepp O, et al. Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res. 2008;64(4):363-371. doi:10.1016/j.jpsychores.2008.01.002

Sprauten M, Haugnes HS, Brydøy M, Kiserud C, Tandstad T, Bjøro T, et al. Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. Ann Oncol. 2015;26(10):2133-2140. doi:10.1093/annonc/mdv328

Winquist EW, Bauman GS, Balogh J. Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review. Am J Clin Oncol. 2001;24(6):603-606. doi:10.1097/00000421-200112000-00015

Cook AM, Dzik-Jurasz AS, Padhani AR, Norman A, Huddart RA. The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. Br J Cancer. 2001;85(11):1624-1626. doi:10.1054/bjoc.2001.2155

Michalecki L, Gabryś D, Kulik R, Wydmański J, Trela K. Radiotherapy induced hip joint avascular necrosis-two cases report. Rep Pract Oncol Radiother. 2011;16(5):198-201. doi:10.1016/j.rpor.2011.04.004

Chang C, ., Greenspan A, ., Beltran J, Gershwin ME. Osteonecrosis. In: Firestein GS, Budd RC, S.E. G, McInnes IB, O’Dell JR, editors. Kelley and Firestein’s Textbook of Rheumatology: Elsevier; 2017. p. 1767-1787.

Petersen PM, Skakkebaek NE, Vistisen K, Rørth M, Giwercman A. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol. 1999;17(3):941-947. doi:10.1200/jco.1999.17.3.941

Joensen UN, Jørgensen N, Rajpert-De Meyts E, Skakkebaek NE. Testicular dysgenesis syndrome and Leydig cell function. Basic Clin Pharmacol Toxicol. 2008;102(2):155-161. doi:10.1111/j.1742-7843.2007.00197.x

Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005;93(2):200-207. doi:10.1038/sj.bjc.6602677

Nord C, Bjøro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol. 2003;44(3):322-328. doi:10.1016/s0302-2838(03)00263-x

Müller J. Impact of cancer therapy on the reproductive axis. Horm Res. 2003;59 Suppl 1:12-20. doi:10.1159/000067835

Ni FD, Hao SL, Yang WX. Molecular insights into hormone regulation via signaling pathways in Sertoli cells: with discussion on infertility and testicular tumor. Gene. 2020;753:144812. doi:10.1016/j.gene.2020.144812

Wiechno P, Demkow T, Kubiak K, Sadowska M, Kamińska J. The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era. Eur Urol. 2007;52(5):1448-1454. doi:10.1016/j.eururo.2007.05.012

Isaksson S, Bogefors K, Ståhl O, Eberhard J, Giwercman YL, Leijonhufvud I, et al. High risk of hypogonadism in young male cancer survivors. Clin Endocrinol (Oxf). 2018;88(3):432-441. doi:10.1111/cen.13534

Sprauten M, Brydøy M, Haugnes HS, Cvancarova M, Bjøro T, Bjerner J, et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol. 2014;32(6):571-578. doi:10.1200/jco.2013.51.2715

Williams DHt, Karpman E, Sander JC, Spiess PE, Pisters LL, Lipshultz LI. Pretreatment semen parameters in men with cancer. J Urol. 2009;181(2):736-740. doi:10.1016/j.juro.2008.10.023

Djaladat H, Burner E, Parikh PM, Beroukhim Kay D, Hays K. The association between testis cancer and semen abnormalities before orchiectomy: a systematic review. J Adolesc Young Adult Oncol. 2014;3(4):153-159. doi:10.1089/jayao.2014.0012

Cvancarova M, Samuelsen SO, Magelssen H, Fosså SD. Reproduction rates after cancer treatment: experience from the Norwegian radium hospital. J Clin Oncol. 2009;27(3):334-343. doi:10.1200/jco.2007.15.3130

Taksey J, Bissada NK, Chaudhary UB. Fertility after chemotherapy for testicular cancer. Arch Androl. 2003;49(5):389-395. doi:10.1080/01485010390219917

Paoli D, Gallo M, Rizzo F, Spanò M, Leter G, Lombardo F, et al. Testicular cancer and sperm DNA damage: short- and long-term effects of antineoplastic treatment. Andrology. 2015;3(1):122-128. doi:10.1111/j.2047-2927.2014.00250.x

Tinkler SD, Howard GC, Kerr GR. Sexual morbidity following radiotherapy for germ cell tumours of the testis. Radiother Oncol. 1992;25(3):207-212. doi:10.1016/0167-8140(92)90270-5

Jonker-Pool G, Van de Wiel HB, Hoekstra HJ, Sleijfer DT, Van Driel MF, Van Basten JP, et al. Sexual functioning after treatment for testicular cancer--review and meta-analysis of 36 empirical studies between 1975-2000. Arch Sex Behav. 2001;30(1):55-74. doi:10.1023/a:1026468707362

Jonker-Pool G, van Basten JP, Hoekstra HJ, van Driel MF, Sleijfer DT, Koops HS, et al. Sexual functioning after treatment for testicular cancer: comparison of treatment modalities. Cancer. 1997;80(3):454-464. doi:10.1002/(sici)1097-0142(19970801)80:3<454::aid-cncr13>3.0.co;2-w

Nappi L, Ottaviano M, Rescigno P, Fazli L, Gleave ME, Damiano V, et al. Long term deficiency of vitamin D in germ cell testicular cancer survivors. Oncotarget. 2018;9(30):21078-21085. doi:10.18632/oncotarget.24925

Wang Z, Li B, Xing J, Gong Z, Xu A, Wang Z. Causes of death after testicular cancer diagnosis: a US population-based analysis. BMC Urol. 2023;23(1):144. doi:10.1186/s12894-023-01309-3

Lauritsen J, Hansen MK, Bandak M, Kreiberg MB, Skøtt JW, Wagner T, et al. Cardiovascular risk factors and disease after male germ cell cancer. J Clin Oncol. 2020;38(6):584-592. doi:10.1200/jco.19.01180

Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513-1523. doi:10.1200/jco.2003.04.173

Dieckmann KP, Struss WJ, Budde U. Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Res. 2011;31(12):4501-4505.

Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18(8):1725-1732. doi:10.1200/jco.2000.18.8.1725

Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol. 2007;18(2):241-248. doi:10.1093/annonc/mdl372

Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89(19):1429-1439. doi:10.1093/jnci/89.19.1429

Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst. 2000;92(14):1165-1171. doi:10.1093/jnci/92.14.1165

Møller H, Mellemgaard A, Jacobsen GK, Pedersen D, Storm HH. Incidence of second primary cancer following testicular cancer. Eur J Cancer. 1993;29a(5):672-676. doi:10.1016/s0959-8049(05)80344-2

Wanderås EH, Fosså SD, Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer. 1997;33(2):253-262. doi:10.1016/s0959-8049(96)00458-3

Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J, Siegert W. Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst. 1995;87(1):58-60. doi:10.1093/jnci/87.1.58

Hunger SP, Sklar J, Link MP. Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of three cases and review of the literature. J Clin Oncol. 1992;10(1):156-163. doi:10.1200/jco.1992.10.1.156

Stewart DJ, Mikhael NZ, Nanji AA, Nair RC, Kacew S, Howard K, et al. Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity. J Clin Oncol. 1985;3(9):1251-1256. doi:10.1200/jco.1985.3.9.1251

Uozumi J, Ueda T, Yasumasu T, Koikawa Y, Naito S, Kumazawa J, et al. Platinum accumulation in the kidney and liver following chemotherapy with cisplatin in humans. Int Urol Nephrol. 1993;25(3):215-220.

Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer. 1999;83(6):860-863. doi:10.1002/(sici)1097-0215(19991210)83:6<860::aid-ijc32>3.0.co;2-l

Milano MT, Dinh PC, Yang H, Zaid MA, Fossa SD, Feldman DR, et al. Solid and hematologic neoplasms after testicular cancer: a US population-based study of 24 900 survivors. JNCI Cancer Spectr. 2020;4(3):pkaa017. doi:10.1093/jncics/pkaa017

van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007;25(28):4370-4378. doi:10.1200/jco.2006.10.5296

Maroto P, García Del Muro X, Valverde C, Pinto A, Sanchez A, Guma J, et al. Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer. Urol Oncol. 2021;39(2):135.e117-135.e123. doi:10.1016/j.urolonc.2020.11.004

Tabernero J, Paz-Ares L, Salazar R, Lianes P, Guerra J, Borrás J, et al. Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. J Urol. 2004;171(1):164-167. doi:10.1097/01.ju.0000099893.79138.55

Theodore C, Terrier-Lacombe MJ, Laplanche A, Benoit G, Fizazi K, Stamerra O, et al. Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy. Br J Cancer. 2004;90(1):55-59. doi:10.1038/sj.bjc.6601464

Del Risco Kollerud R, Ruud E, Haugnes HS, Cannon-Albright LA, Thoresen M, Nafstad P, et al. Family history of cancer and risk of paediatric and young adult’s testicular cancer: A Norwegian cohort study. Br J Cancer. 2019;120(10):1007-1014. doi:10.1038/s41416-019-0445-2

Carmignani L, Bozzini G. Re: Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J. D. Raman, C. F. Nobert and M. Goldstein. J Urol. 2006;175(4):1574; author reply 1574. doi:10.1016/s0022-5347(05)00703-2

Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer. 1997;80(10):1954-1960.

Kaasa S, Aass N, Mastekaasa A, Lund E, Fosså SD. Psychosocial well-being in testicular cancer patients. Eur J Cancer. 1991;27(9):1091-1095. doi:10.1016/0277-5379(91)90299-s

Schepisi G, De Padova S, De Lisi D, Casadei C, Meggiolaro E, Ruffilli F, et al. Psychosocial issues in long-term survivors of testicular cancer. Front Endocrinol (Lausanne). 2019;10:113. doi:10.3389/fendo.2019.00113

Smith AB, Rutherford C, Butow P, Olver I, Luckett T, Grimison P, et al. A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors. Psychooncology. 2018;27(4):1129-1137. doi:10.1002/pon.4596

Fosså SD, Dahl AA, Loge JH. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol. 2003;21(7):1249-1254. doi:10.1200/jco.2003.08.163

Shrem NS, Wood L, Hamilton RJ, Kuhathaas K, Czaykowski P, Roberts M, et al. Testicular cancer survivorship: long-term toxicity and management. Can Urol Assoc J. 2022;16(8):257-272. doi:10.5489/cuaj.8009

Dahl AA, Mykletun A, Fosså SD. Quality of life in survivors of testicular cancer. Urol Oncol. 2005;23(3):193-200. doi:10.1016/j.urolonc.2005.03.004

Wang AW, Hoyt MA. Cancer-related masculinity threat in young adults with testicular cancer: the moderating role of benefit finding. Anxiety Stress Coping. 2020;33(2):207-215. doi:10.1080/10615806.2020.1713447

Carpentier MY, Fortenberry JD. Romantic and sexual relationships, body image, and fertility in adolescent and young adult testicular cancer survivors: a review of the literature. J Adolesc Health. 2010;47(2):115-125. doi:10.1016/j.jadohealth.2010.04.005

De Padova S, Casadei C, Berardi A, Bertelli T, Filograna A, Cursano MC, et al. Caregiver emotional burden in testicular cancer patients: from patient to caregiver support. Front Endocrinol (Lausanne). 2019;10:318. doi:10.3389/fendo.2019.00318

Skoogh J, Steineck G, Johansson B, Wilderäng U, Stierner U. Psychological needs when diagnosed with testicular cancer: findings from a population-based study with long-term follow-up. BJU Int. 2013;111(8):1287-1293. doi:10.1111/j.1464-410X.2012.11696.x

Doyle R, Craft P, Turner M, Paterson C. Identifying the unmet supportive care needs of individuals affected by testicular cancer: a systematic review. J Cancer Surviv. 2022. doi:10.1007/s11764-022-01219-7

Gandaglia G, Becker A, Trinh QD, Abdollah F, Schiffmann J, Roghmann F, et al. Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis. Eur J Surg Oncol. 2014;40(1):103-112. doi:10.1016/j.ejso.2013.09.019

Lavi A, Clark R, Ly TL, Nair SM, Hetou K, Haan M, et al. Long-term testis cancer survivors in Canada-mortality risks in a large population-based cohort. Eur Urol Open Sci. 2020;22:54-60. doi:10.1016/j.euros.2020.10.005

Fung C, Travis LB. Testicular cancer survivorship: looking back to move forward. J Clin Oncol. 2021;39(32):3531-3534. doi:10.1200/jco.21.01984

Hellesnes R, Myklebust T, Fosså SD, Bremnes RM, Karlsdottir Á, Kvammen Ø, et al. Testicular cancer in the Cisplatin era: causes of death and mortality rates in a population-based cohort. J Clin Oncol. 2021;39(32):3561-3573. doi:10.1200/jco.21.00637

Downloads

Published

2024-06-20

How to Cite

Pisino, M., & Nappi, L. (2024). Survivorship Issues in Testicular Cancer. Canadian Oncology Today, 1(2), 28–36. https://doi.org/10.58931/cot.2024.1223

Issue

Volume 1, Issue 2, Summer 2024

Section

Articles

License

Copyright (c) 2024 Canadian Oncology Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.